key: cord-0768461-2hzb7amy
authors: Kang, Keren; Huang, Lingfang; Ouyang, Chaolin; Du, Jiaming; Yang, Bin; Chi, Yaqin; He, Shuyu; Ying, Le; Chen, Guoling; Wang, Jihua
title: Development, Performance Evaluation and Clinical Application of A Rapid SARS‐CoV‐2 IgM and IgG Test Kit Based on Automated Fluorescence Immunoassay
date: 2020-11-24
journal: J Med Virol
DOI: 10.1002/jmv.26696
sha: 4f696145c7f68e85c1ef82cda953919155d6a5c8
doc_id: 768461
cord_uid: 2hzb7amy

The ongoing COVID‐19 epidemic has made a huge impact on health, economies, and societies all over the world. Although RT‐PCR‐based nucleic acid detection has been primarily used in the diagnosis of COVID‐19, it is time‐consuming with limited application scenarios and must be operated by qualified personnel. Antibody test, particularly point‐of‐care antibody testing, is a suitable complement to nucleic acid test as it provides rapid, portable, and cost‐effective detection of infections. In this study, a rapid antibody test kit was developed based on fluorescence immunochromatography for the sensitive, accurate, and automated detection of IgM and IgG antibodies against SARS‐CoV‐2 in human serum, plasma, and whole blood samples within 10 minutes. The sensitivity, specificity, precision, and stability of the test kit were of good performance. No cross‐activity and no interference was observed. In the multiple‐center parallel study, 223 samples from hospitalized patients were used to evaluate the clinical specificity of the test. Both SARS‐CoV‐2 IgM and IgG achieved a clinical specificity of 98.21%. The clinical sensitivities of SARS‐CoV‐2 IgM and IgG were 79.54% and 87.45%, respectively, among 733 RT‐PCR confirmed SARS‐Cov‐2 samples. For the combined IgM and IgG assays, the sensitivity and specificity were 89.22% and 96.86%, respectively. Our results demonstrate that the combined use of IgM and IgG could serve as a more suitable alternative detection method for COVID‐19 patients, and the developed kit is of great public health significance for the prevention and control of the COVID‐19 pandemic. This article is protected by copyright. All rights reserved.

Coronavirus disease 2019 (COVID-19) is a novel infectious disease, which has plunged the whole world into a state of emergency and declared as a global pandemic by the World Health Organization. The outbreak and prevalence of COVID-19 have brought severe challenges to the health care system and made a huge impact on the world economy and society. As of 5 August 2020, more than 200 countries and territories have officially reported 18354342 confirmed cases and 696147 deaths [1] , the pandemic remains a public health emergency of international concern.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19. It belongs to the genus β-coronavirus, with a single-stranded and positive-sense RNA viral genome of ~30 kilobases [2] . SARS-CoV-2 encodes four structural proteins, including the spike protein (S), envelope protein (E), membrane protein (M), and nucleocapsid (N) protein, which are involved in transcription, assembly, budding, envelope formation, and the pathogenesis of the virus [2] [3] .

The accurate, sensitive, and rapid detection of SARS-CoV-2 is of great significance for the prevention and control of the COVID-19 pandemic. In the past few months, various commercially available COVID-19 test kits have been developed to meet the urgent need of several countries. These detection techniques fall into two main categories: nucleic acid detection and immunological detection. The nucleic acid test detects SARS-CoV-2 viral RNA based on reverse transcription-polymerase chain reaction (RT-PCR), isothermal amplification, genome sequencing, or other methods. The target of immunological detection is SARS-CoV-2 viral protein antigens or antibodies produced in response to the infection. Immunological detection methods mainly include Accepted Article with (T/C)/CO < 1.0 were considered negative, (T/C)/CO ≥ 1.0 were considered positive.

For investigating the sensitivity of the assay, three positive samples determined by commercial SARS-CoV-2 antibody test kits were diluted with negative serum at different concentrations. Three replicates were prepared for each dilution and each sample was tested 20 times. The limit of detection was determined as the antibody level with a positive rate greater than 95%. Two negative reference samples and four weakly positive reference samples with different concentration gradients of interfering substances were evaluated to investigate interference. These interfering substances include bilirubin, hemoglobin, triglyceride, rheumatoid factor, anti-nuclear antibody, anti-mitochondrial antibody, HAMA, histamine dihydrochloride, α-interferon, zanamivir, ribavirin, oseltamivir, peramivir, virus were also evaluated to investigate the cross-reactivity of the assay.

SARS-CoV-2 is the third highly pathogenic and transmissible coronavirus, after the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) in humans [8] . Accurate identification of SARS-CoV-2 infection is essential for an effective diagnosis of COVID-19, and this is important not only for the patients but also for public health.

The positive result of viral nucleic acid testing is the key and direct evidence of SARS-CoV-2 infection, and it is considered the gold standard for the diagnosis of COVID-19. However, it is difficult for some countries or regions to build up the ability to cope with a large number of patients in a short period under the epidemic because of the high need for sophisticated equipment and specialized personnel to carry out nucleic acid testing. Besides, many factors could contribute to false-negative results [9] , such as the different disease courses, specimen collection sites, non-standard operation, or even drugs. Therefore, it is a critical need to develop a supplementary detection method to compensate for these limitations.

In China, according to the guideline of diagnosis and treatment of COVID-19 (version 8) [10] , either etiological or serological evidence can be used as the diagnostic criteria for suspected cases. Besides real-time fluorescence quantitative RT-PCR and gene sequencing, SARS-CoV-2 specific IgM and IgG antibody detection can also be used as an important tool to confirm suspected patients.

Antibodies could be produced by the immune system after pathogen infection and could be tested by immunological detection methods. Since the samples used for antibody testing is blood, compared to nasopharyngeal swabs, sample collection is easier to control and less affected by collection location and operational errors, ensuring repeatability of test results. To some extent, it can also reduce biosecurity risks for the test operators. Nevertheless, antibody assays may give false-positive results in clinical practice because of interfering substances in patients and cross-reaction with other viruses. Hence, the SARS-CoV-2 antibody test kit needs to be fully evaluated to avoid false-positive results but with excellent sensitivity and specificity in COVID-19 detection.

In this study, we developed SARS-CoV-2 IgM and IgG immunoassays for the rapid test of COVID-19. The assays were based on fluorescence immunochromatography and operated on an auto-immunofluorescence analyzer. The specific IgM and IgG antibodies could be automatically measured and the whole detection process takes about 10 minutes as compared to 3-4 hours of performing a nucleic acid test. Although some commercial immunoassays have been produced based on CLIA and colloidal gold method, our assay is cheaper and easier to build capacity to detect SARS-CoV-2 antibodies than CLIA and is especially suitable for developing countries and areas with limited laboratory conditions. This assay is more stable and provides quantitative detection results as compared to the colloidal gold method that must be observed with the naked eye. Besides, our newly developed kits are suitable for the different types of Finecare TM FIA Meters and immunofluorescence analyzers with single-channel can also be selected according to actual need. Since many factors such as other types of coronavirus infections and autoimmune diseases, could play a role in the determination of the specificity of SARS-CoV-2 IgM and IgG immunoassays [11] [12] [13] , we verified the interference and cross-reactivity of our assays. Interestingly, both assays showed excellent and reliable test results comparable to the nucleic acid test in the detection of the SARS-CoV-2 virus. Also, we performed multicenter, large sample trials across 9 hospitals in

China. As a result, the specificity of SARS-CoV-2 IgM and IgG assays was both 98.21%, and the clinical sensitivities of SARS-CoV-2 IgM and IgG were 79.54% and 87.45%, respectively.

Based on previous studies of SARS-CoV, the median serum conversion time of IgM and IgG was at least 7-10 days after onset, and IgM and IgG could last for 2-3 years [14] [15] . Although several studies on SARS-CoV-2 antibody detection have been published, the longitudinal change of SARS-CoV-2 antibodies is still debated. To verify the suitability of our test kit at different stages of the disease, we tested the sensitivity of the assay in patients at different infection time points. We observed that IgM and IgG were detectable as early as day 1 after onset in some patients. However, similar to some other studies on SARS-CoV-2 antibody [16] [17] , the sensitivity was low for either IgM or IgG within the first week, and the positivity rate showed little difference between IgM and IgG, suggesting that IgG could appear immediately after IgM or at the same time. The positivity rate of IgM and IgG rapidly increased to more than 80% in the second-week post-onset. IgM peaked in the third week, and then kept decreasing but the positive rate remained higher than 75% at 49 days after onset. While IgG positive rate remained high after the first-week post-onset. Combined IgM/IgG tests performed best in almost all stages of the onset of COVID-19. In addition, we found that the positive rate of SARS-CoV-2 IgM was lower in the mild cases than in the moderate/severe cases within 5 weeks after onset, and there were statistical differences at 4 and 5 weeks after onset. The same trend was not shown for more than five weeks, possibly because of the small sample size. For IgG, there was no significant difference between the two groups. Since specific IgG appears nearly IgM in COVID-19 patients, combined IgM/IgG performed best in either mild or moderate/severe cases. Therefore, we recommend the combined use of IgM and IgG rather than individual testing of IgM or IgG for all patients. Taken together, our newly developed test kit provides a suitable point-of-care testing of COVID-19 patients after the first week of illness.

In this COVID-19 pandemic, the need for antibody testing among asymptomatic and symptomatic individuals and their close contacts would be critical to combating the pandemic. Tables 

World Health Organization. Coronavirus disease (COVID-19) situation report-198

The architecture of SARS-CoV-2 transcriptome

Human Coronaviruses: A review of virus-host interactions

Assay techniques and test development for COVID-19 diagnosis

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Rapid and sensitive detection of anti-SARS-CoV-2 IgG using lanthanide-doped nanoparticles-based lateral flow immunoassay

National Health Commission of the People's Republic of China. The guideline of diagnosis and treatment of COVID-19 (version 6)

Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia

Potential false-negative nucleic acid testing results for Severe Acute Respiratory Syndrome Coronavirus 2 from thermal inactivation of samples with low viral loads

National Health Commission of the People's Republic of China. The guideline of diagnosis and treatment of COVID-19

animal coronaviruses: implication for SARS diagnosis

False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by western blotting with recombinant SARS-CoV spike polypeptide

Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases

Duration of antibody responses after severe acute respiratory syndrome

Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance

Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Eleven faces of coronavirus disease 2019